RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30163% above fair value
$1.16−0.06 (-4.92%)
Close on Nov 12, 2026Market cap $52.35MP/E –Yield –
RenovoRx enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
RenovoRx's enterprise value was $45.57M on Nov 11, 2026, against $23.58M a year earlier. Over the last 5 years it ranged from -$272.24K to $77.61M, with a median of $16.88M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $45.57M | +119.7% |
| 2025 | Dec 31, 2025 | $20.75M | -3.1% |
| 2024 | Dec 31, 2024 | $21.40M | +0.6% |
| 2023 | Dec 29, 2023 | $21.26M | +60.8% |
| 2022 | Dec 30, 2022 | $13.22M | -47.9% |
| 2021 | Dec 31, 2021 | $25.39M | – |
See a number that looks wrong?